Javascript must be enabled to continue!
HUMAN TENOCYTES ARE STIMULATED TO PROLIFERATE BY ACETYLCHOLINE THROUGH AN EGFR SIGNALLING PATHWAY
View through CrossRef
IntroductionStudies on human patellar and Achilles tendons have shown that tendon cells not only have the capacity to produce acetylcholine (ACh) but also express muscarinic ACh receptors (mAChRs), of subtype M2 (M2R), and that both the production and receptor expression seem to be increased in tendinosis. Hypercellularity and angiogenesis are key histopathologic features in tendinosis tissue. In this study, we aimed at testing the hypothesis that ACh increases the proliferation rate of tenocytes through mAChR stimulation, as well as investigating whether this mechanism is mediated by the extracellular activation (phosphorylation) of the epidermal growth factor receptor (EGFR), which has been shown to elicit DNA synthesis and cell proliferation in other fibroblastic cells types, through an intracellular pathway including activation/phosphorylation of the mitogen activated protein kinases ERK1/2.MethodsHuman Achilles tenocytes were seeded in cell culture plates and incubated in serum-starved conditions. The cells were pre-treated with the EGFR inhibitor AG1478, the matrix metalloproteinase (MMP) inhibitor GM6001 or the mAChR antagonist atropine. The cells were then stimulated with ACh (10−6 M) or the vehicle. To determine the levels of phospho-ERK1/2 and phospho-EGFR, Western blot analysis was performed. 5-Bromo-2′-deoxy-uridine (BrdU) and crystal violet staining were used to assess cell proliferation and cell viability, respectively.ResultsThe primary human tendon cells in culture expressed enzymes related to ACh synthesis (choline acetyltransferase and vesicular acetylcholine transporter), along with vimentin and tenomodulin, which confirm the tenocyte phenotype. The cells also expressed the M2R. By administering exogenous ACh, the tenocytes were stimulated to significantly proliferate and increase in viability. In addition, Western blot showed that ACh stimulation resulted in increased phosphorylation of both EGFR and ERK1/2. When the cells were exposed to atropine, or the EGFR-blocking substance, the proliferative effect of ACh decreased. Simultaneously, the increase in ERK1/2 phosphorylation induced by incubation with ACh was effectively blocked in the presence of the mAChR antagonist atropine. Inhibition of either EGFR or MMP with specific blockers reduced the phosphorylation of ERK1/2.DiscussionBased on the results of the present study, as well as from previously established studies, we propose that human tenocytes, with their innate ability to produce ACh, increase ACh production during tendinosis development. Via an autocrine loop, the ACh produced by tenocytes stimulates mAChRs on the cell surface, thereby activating MMPs to cleave a cell surface-associated EGFR ligand. The ligand then binds to EGFR which in turn after activation increases ERK1/2 phosphorylation, leading to the increased cell proliferation and hypercellularity as seen in tendinosis (figure 1). In an early stage of tendinosis, hypercellularity might be a part of a healing or adaptive response, but in the chronic stage excessive tenocyte proliferation could be detrimental to tendon structure and function. The non-neuronal cholinergic system of tendon tissue is thus a possible target for future modulation of these processes in tendinosis.Figure 1.Schematic drawing of proposed cellular pathways involved in ACh-induced proliferation of human tendon cells. ACh stimulates membrane bound muscarinic ACh receptors (mAChRs) that in turn activate matrix metalloproteinases (MMPs) to cleave a cell surface-associated EGFR ligand. The ligand then binds to EGFR which in turn increases cell proliferation through phosphorylation of the mitogen-activated protein kinases ERK1/2.
Title: HUMAN TENOCYTES ARE STIMULATED TO PROLIFERATE BY ACETYLCHOLINE THROUGH AN EGFR SIGNALLING PATHWAY
Description:
IntroductionStudies on human patellar and Achilles tendons have shown that tendon cells not only have the capacity to produce acetylcholine (ACh) but also express muscarinic ACh receptors (mAChRs), of subtype M2 (M2R), and that both the production and receptor expression seem to be increased in tendinosis.
Hypercellularity and angiogenesis are key histopathologic features in tendinosis tissue.
In this study, we aimed at testing the hypothesis that ACh increases the proliferation rate of tenocytes through mAChR stimulation, as well as investigating whether this mechanism is mediated by the extracellular activation (phosphorylation) of the epidermal growth factor receptor (EGFR), which has been shown to elicit DNA synthesis and cell proliferation in other fibroblastic cells types, through an intracellular pathway including activation/phosphorylation of the mitogen activated protein kinases ERK1/2.
MethodsHuman Achilles tenocytes were seeded in cell culture plates and incubated in serum-starved conditions.
The cells were pre-treated with the EGFR inhibitor AG1478, the matrix metalloproteinase (MMP) inhibitor GM6001 or the mAChR antagonist atropine.
The cells were then stimulated with ACh (10−6 M) or the vehicle.
To determine the levels of phospho-ERK1/2 and phospho-EGFR, Western blot analysis was performed.
5-Bromo-2′-deoxy-uridine (BrdU) and crystal violet staining were used to assess cell proliferation and cell viability, respectively.
ResultsThe primary human tendon cells in culture expressed enzymes related to ACh synthesis (choline acetyltransferase and vesicular acetylcholine transporter), along with vimentin and tenomodulin, which confirm the tenocyte phenotype.
The cells also expressed the M2R.
By administering exogenous ACh, the tenocytes were stimulated to significantly proliferate and increase in viability.
In addition, Western blot showed that ACh stimulation resulted in increased phosphorylation of both EGFR and ERK1/2.
When the cells were exposed to atropine, or the EGFR-blocking substance, the proliferative effect of ACh decreased.
Simultaneously, the increase in ERK1/2 phosphorylation induced by incubation with ACh was effectively blocked in the presence of the mAChR antagonist atropine.
Inhibition of either EGFR or MMP with specific blockers reduced the phosphorylation of ERK1/2.
DiscussionBased on the results of the present study, as well as from previously established studies, we propose that human tenocytes, with their innate ability to produce ACh, increase ACh production during tendinosis development.
Via an autocrine loop, the ACh produced by tenocytes stimulates mAChRs on the cell surface, thereby activating MMPs to cleave a cell surface-associated EGFR ligand.
The ligand then binds to EGFR which in turn after activation increases ERK1/2 phosphorylation, leading to the increased cell proliferation and hypercellularity as seen in tendinosis (figure 1).
In an early stage of tendinosis, hypercellularity might be a part of a healing or adaptive response, but in the chronic stage excessive tenocyte proliferation could be detrimental to tendon structure and function.
The non-neuronal cholinergic system of tendon tissue is thus a possible target for future modulation of these processes in tendinosis.
Figure 1.
Schematic drawing of proposed cellular pathways involved in ACh-induced proliferation of human tendon cells.
ACh stimulates membrane bound muscarinic ACh receptors (mAChRs) that in turn activate matrix metalloproteinases (MMPs) to cleave a cell surface-associated EGFR ligand.
The ligand then binds to EGFR which in turn increases cell proliferation through phosphorylation of the mitogen-activated protein kinases ERK1/2.
Related Results
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.
8563 Background: There are limited reports on biomarker studies of non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutation (exon...
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract 557: Noninvasive analysis of acquired resistance to EGFR-TKI
Abstract
BACKGROUND
Epidermal growth factor receptor (EGFR) T790M mutation is associated with EGFR tyrosine kinase inhibitors (EGFR-TKIs) resistance i...
Molecular Signalling in the Cnidarian-Dinoflagellate Symbiosis
Molecular Signalling in the Cnidarian-Dinoflagellate Symbiosis
<p><strong>The cnidarian-dinoflagellate endosymbiosis enables the success of coral reefs, though there are still major knowledge gaps concerning the molecular and cellu...
Abstract TP356: Renal Function and In-Hospital Outcomes in Patients With Acute Cerebrovascular Disease: Results From Chinese Stroke Center Alliance
Abstract TP356: Renal Function and In-Hospital Outcomes in Patients With Acute Cerebrovascular Disease: Results From Chinese Stroke Center Alliance
Background and Purpose:
To investigate the association of renal function with in-hospital death and recurrent stroke in patients with acute stroke.
...
Abstract A142: Molecular modeling approach to the rational design of promiscuous quinazoline-based EGFR inhibitors
Abstract A142: Molecular modeling approach to the rational design of promiscuous quinazoline-based EGFR inhibitors
Abstract
Solid tumors at the advanced stages are often characterized by the overexpression of tyrosine kinase receptors that stimulate growth through the MAP kinase ...
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract 1769: The clinical outcome of stage I lung adenocarcinoma patients with or without activating EGFR mutation
Abstract
Purpose: Advanced stage lung adenocarcinoma patients with activating EGFR mutation have better survival result after EGFR tyrosine kinase inhibitor develope...
Abstract 2113: KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR
Abstract 2113: KRAS amplification mediates resistance to osimertinib in acquired afatinib-resistant NSCLC harboring exon 19 deletion/T790M in EGFR
Abstract
Background: The second mutation of T790M in epidermal growth factor receptor (EGFR) exon 20 mediates resistance to first- and second-generation EGFR tyrosin...
Data from ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance
Data from ANXA1 Binds and Stabilizes EGFR to Promote Nasopharyngeal Carcinoma Radioresistance
<div>Abstract<p>Radioresistance is a serious obstacle to successful nasopharyngeal carcinoma (NPC) treatment. Annexin A1 (ANXA1) is associated with EGFR and is involved...

